SUO 2018: WUOF Lecture: Smart Care of Prostate Cancer Patients Using Artificial Intelligence & IoT
Phoenix, Arizona (UroToday.com) Ji Youl Lee, MD, of Seoul St. Mary’s Hospital, was the WUOF Invited Lecturer today. His talk was a brief overview of the potential of artificial intelligence and technology in the management of prostate cancer. He set the talk in the context of work he is doing in Korea.
SUO 2018: TLD-1433 Photodynamic Therapy for BCG-Unresponsive NMIBC - A Phase IB Clinical Study
Phoenix, Arizona (UroToday.com) There are many novel chemotherapeutic and immunotherapeutic agents being investigated for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Photodynamic therapy (PDT) offers a novel approach whereby laser light is used to activate an otherwise non-toxic photosensitizer to destroy tumor vasculature and to induce an immune response. TLD-1433 is a ruthenium-based photodynamic compound with preferential uptake by bladder cancer cells. TLD-1433 is activated by Green light (525 nm) causing the release of free radicals, which eventually cause cell death.
SUO 2018: Phase III Trial of Intravenous Mannitol vs. Placebo During Nephron Sparing Surgery: 3 Year Outcomes
Phoenix, Arizona (UroToday.com) In a prospective, randomized, placebo-controlled, double-blind trial it was demonstrated that patients with normal kidney function who received mannitol during nephron-sparing surgery did not manifest improved kidney function compared to patients who received placebo at 6 weeks and 6 months following surgery. Despite these findings, some have suggested that patients with comorbidities, including lower preoperative estimated glomerular filtration rate, may still derive some benefit. In this presented study, these patients were reexamined at the 3-year follow-up time point and their long-term renal function outcomes were assessed.
SUO 2018: Diet in GU Cancers: Known Unknowns and Unknown Unknowns
Phoenix, Arizona (UroToday.com) Dr. Dorff gave an overview of the role of diet in genitourinary cancers. Many studies have been done trying to elucidate the role of different dietary factors in prostate cancer. These include studies assessing the role of fat, lycopene, vegetables, soy, dairy products, and vitamin E. It is also known that changing the diets results in the change of cancer risk. For example, Japanese men who live in Hawaii, and do not eat a typical Japanese diet, but rather a diet which resembles a North-American diet, have a much higher risk to develop cancer (1). Data has also shown that specific bacteria are associated with a healthier diet (green vegetables, fiber and nuts) and could lower risk of prostate cancer (2).
SUO 2018: Genomics of Upper Tract Disease
Phoenix, Arizona (UroToday.com) Dr. Coleman reviewed the contemporary understanding of genomics of upper tract disease and implications for future targeted therapies. It is presently understood that cancers arising from the urothelium of the bladder and upper tract are morphologically similar, yet clinical findings also reveal important biological differences. Compared to bladder urothelial carcinoma (UC), upper tract urothelial carcinoma (UTUC) is more often high grade (70% vs 30%), associated with environmental exposures to toxins (aristolochic acid, phenacetin, blackfoot disease), associated with hereditary patterns (Lynch Syndrome, MSH mutations) and with better cancer-specific mortality.
SUO 2018: Role of Adjuvant Therapy - POUT Trial
Phoenix, Arizona (UroToday.com) The management of patients with upper tract urothelial carcinoma (UTUC) is controversial due to lack of level 1 evidence and rarity of the disease. The standard of care for patients with high-grade disease or those suspected to have invasive disease is nephroureterectomy (NU) with some evidence in support of neoadjuvant or adjuvant platinum-based chemotherapy. During the panel case discussion on management of high-risk UTUC and the role of perioperative chemotherapy in the bladder cancer session at SUO 2018, Dr. Sandy Srinivas, a medical oncologist at Stanford University summarized the results from POUT trial.
SUO 2018: Neoadjuvant Chemotherapy Prior to Nephroureterectomy
Phoenix, Arizona (UroToday.com) The role of neoadjuvant chemotherapy (NAC) in the management of patients with high-grade upper tract urothelial carcinoma (UTUC) remains incompletely understood. Dr. Jean Hoffman-Censits, from Johns Hopkins University, discussed the current data that support the use of NAC in UTUC as part of the Bladder Cancer Session at the 2018 meeting of the Society of Urologic Oncology.